Patents Assigned to Oncogenex Technologies Inc.
  • Method for Selecting Patient Subpopulation for Custirsen Treatment
    Publication number: 20170083675
    Abstract: A method of determining if a cancer patient is susceptible to survival prolongation if treatment is augmented with a clusterin-inhibiting pharmaceutical is provided. The method involves measurement of various patient data and a systematic approach to the analysis. A computer-aided system is also provided.
    Type: Application
    Filed: December 30, 2015
    Publication date: March 23, 2017
    Applicant: OncoGenex Technologies Inc.
    Inventors: Cindy Jacobs, Brent A. Blumenstein
  • Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors
    Patent number: 8987223
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 24, 2015
    Assignee: Oncogenex Technologies Inc.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Antisense formulation
    Patent number: 8383336
    Abstract: A room temperature stable and minimal aggregate liquid formulation comprises an oligonucleotide comprising Seq ID No. 1: or comprising a variant oligonucleotide in which no more than 3 non-sequential bases are different from Seq. ID NO. 1 and an aqueous carrier comprising a aggregation-preventing compound selected from the group consisting of mono and disaccharides and/or sugar alcohols.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: February 26, 2013
    Assignee: Oncogenex Technologies Inc.
    Inventors: Thomas K. Hayes, Nicole D. Krilla, Lori Nixon